XFORX4 Pharmaceuticals, Inc

Nasdaq x4pharma.com


$ 1.20 $ 0.00 (0.42 %)    

Thursday, 18-Apr-2024 15:59:15 EDT
QQQ $ 422.80 $ -2.43 (-0.57 %)
DIA $ 377.76 $ 0.39 (0.1 %)
SPY $ 499.54 $ -1.03 (-0.21 %)
TLT $ 88.82 $ -0.45 (-0.5 %)
GLD $ 220.32 $ 0.75 (0.34 %)
$ 1.2
$ 1.22
$ 0.00 x 0
$ 0.00 x 0
$ 1.18 - $ 1.24
$ 0.57 - $ 2.58
1,732,822
na
213.37M
$ 1.03
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-21-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-04-2023 03-31-2023 10-Q
5 03-21-2023 12-31-2022 10-K
6 11-03-2022 09-30-2022 10-Q
7 08-04-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 03-17-2022 12-31-2021 10-K
10 11-04-2021 09-30-2021 10-Q
11 08-03-2021 06-30-2021 10-Q
12 05-06-2021 03-31-2021 10-Q
13 03-19-2021 12-31-2020 10-K
14 11-05-2020 09-30-2020 10-Q
15 08-04-2020 06-30-2020 10-Q
16 05-07-2020 03-31-2020 10-Q
17 03-12-2020 12-31-2019 10-K
18 11-07-2019 09-30-2019 10-Q
19 08-07-2019 06-30-2019 10-Q
20 05-15-2019 03-31-2019 10-Q
21 03-11-2019 12-31-2018 10-K
22 11-09-2018 09-30-2018 10-Q
23 08-13-2018 06-30-2018 10-Q
24 05-10-2018 03-31-2018 10-Q
25 03-09-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-x4-pharmaceuticals-maintains-3-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and maintains ...

 earnings-scheduled-for-march-21-2024

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per s...

 x4-pharmaceuticals-q4-eps-010-beats-015-estimate

X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(...

 b-riley-securities-downgrades-x4-pharmaceuticals-to-neutral-lowers-price-target-to-1

B. Riley Securities analyst Kalpit Patel downgrades X4 Pharmaceuticals (NASDAQ:XFOR) from Buy to Neutral and lowers the pric...

 why-bluebird-bio-shares-are-trading-higher-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from ...

 why-green-giant-shares-are-trading-lower-by-around-37-here-are-20-stocks-moving-premarket

Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Gre...

 saturday-x4-pharmaceuticals-announced-presentation-of-additional-data-from-mavorixafor-phase-2-trial-in-chronic-neutropenia-at-ash-2023

Initial data continue to support advancement of mavorixafor into pivotal, global Phase 3 trial in certain chronic neutropenic...

 earnings-scheduled-for-november-9-2023

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on re...

 x4-pharmaceuticals-q3-eps-001-beats-015-estimate-cash-and-equivalents-1427m

X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION